Literature DB >> 22670519

[Association of chromosome 8q24 variants with prostate cancer risk in the Siberian region of Russia and meta-analysis].

N A Os'kina, U A Boiarskikh, A F Lazarev, V D Petrova, D I Ganov, O G Tonacheva, G I Lifshits, M L Filipenko.   

Abstract

Compelling evidence demonstrates chromosome 8q24 as a prostate cancer susceptibility locus. In present work we studied whether the common variants of 8q24 region, rs6983267 and rs1447295, were associated with the sporadic prostate cancer risk in the Russian population. Polymorphisms were genotyped in 393 case and 384 control Russian Caucasian men from Siberia region. The A allele of rs1447295 was significantly associated with the risk of prostate cancer (OR[CI 95%] = 1.74 [1.26-2.4], p = 7.8 x 10(-4)). A common G-A haplotype for rs6983267 - rs1447295 also showed an association with prostate cancer risk in Russian population (OR[CI 95%] = 2.03 [1.1 - 3.75], p = 0.02). We performed a meta-analysis combining our results with previous studies to evaluate the association between studied SNPs and prostate cancer risk. Meta-analysis has strongly supported the association for these SNPs (p < 10(-6)). Accordingly our study confirms the association between chromosome 8q24 and prostate cancer risk.

Entities:  

Mesh:

Year:  2012        PMID: 22670519

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  2 in total

1.  Common variants at 8q24 are associated with prostate cancer risk in Serbian population.

Authors:  Ana S Branković; Goran N Brajušković; Jovan D Mirčetić; Zorana Z Nikolić; Predrag B Kalaba; Vinka D Vukotić; Saša M Tomović; Snežana J Cerović; Zoran A Radojičić; Dušanka L J Savić-Pavićević; Stanka P Romac
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

2.  A duplex probe-directed recombinase amplification assay for detection of single nucleotide polymorphisms on 8q24 associated with prostate cancer.

Authors:  Qingxia Duan; Xinna Li; Xiaozhou He; Xinxin Shen; Yu Cao; Ruiqing Zhang; Xueding Bai; Jinyan Zhang; Xuejun Ma
Journal:  Braz J Med Biol Res       Date:  2020-11-27       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.